Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

Response Adapted Induction Therapy for Multiple Myeloma

Jason Valent, MD, Christy Samaras, DO, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Brian J. Bolwell, MD, Janice Reed, RN, Mary Ann Karam, RN, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Mitchell R. Smith, MD PhD, Hien K. Liu, MD, Frederic J Reu

Blood (2015) 126 (23): 3327.

https://doi.org/10.1182/blood.V126.23.3327.3327

Published: 2015

Journal Articles

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Frederic J. Reu, MD, Jason Valent, MD, Ehsan Malek, MD, Ronald M. Sobecks, MD, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Jamie Elberson, RN, Sherry Fada, Hien K. Liu, MD, Christy Samaras, DO, Mitchell R. Smith, MD PhD

Blood (2015) 126 (23): 4221.

https://doi.org/10.1182/blood.V126.23.4221.4221

Published: 2015

Journal Articles

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Mayur Narkhede, MD, Jason Valent, MD, Chad Cummings, MBA, Katherine Glass, MPH, MS, Debbie Hastings, Beth Faiman, PhD, CNP, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt E. Kalaycio, MD, Brian J. Bolwell, MD, Mitchell R. Smith, MD PhD, Hien K. Duong, MD, Christy Samaras, DO, Frederic J. Reu, MD

Blood (2014) 124 (21): 2620.

https://doi.org/10.1182/blood.V124.21.2620.2620

Published: 2014

NARROW

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Response-Adapted Therapy for Newly Diagnosed Myeloma

Response Adapted Induction Therapy for Multiple Myeloma

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Email alerts

ASH Publications

American Society of Hematology

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Response-Adapted Therapy for Newly Diagnosed Myeloma

Response Adapted Induction Therapy for Multiple Myeloma

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only